AU2003268020A1 - Treatment of depression secondary to pain (dsp) - Google Patents

Treatment of depression secondary to pain (dsp) Download PDF

Info

Publication number
AU2003268020A1
AU2003268020A1 AU2003268020A AU2003268020A AU2003268020A1 AU 2003268020 A1 AU2003268020 A1 AU 2003268020A1 AU 2003268020 A AU2003268020 A AU 2003268020A AU 2003268020 A AU2003268020 A AU 2003268020A AU 2003268020 A1 AU2003268020 A1 AU 2003268020A1
Authority
AU
Australia
Prior art keywords
pain
depression
milnacipran
dsp
serotonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003268020A
Other languages
English (en)
Inventor
Jay D. Kranzler
Srinivas G. Rao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cypress Bioscience Inc
Original Assignee
Cypress Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cypress Bioscience Inc filed Critical Cypress Bioscience Inc
Publication of AU2003268020A1 publication Critical patent/AU2003268020A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003268020A 2002-07-24 2003-07-24 Treatment of depression secondary to pain (dsp) Abandoned AU2003268020A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39867602P 2002-07-24 2002-07-24
US60/398,676 2002-07-24
US44303503P 2003-01-28 2003-01-28
US60/443,035 2003-01-28
PCT/US2003/023088 WO2004009069A1 (fr) 2002-07-24 2003-07-24 Traitement de la depression consecutive a la douleur

Publications (1)

Publication Number Publication Date
AU2003268020A1 true AU2003268020A1 (en) 2004-02-09

Family

ID=30773102

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003268020A Abandoned AU2003268020A1 (en) 2002-07-24 2003-07-24 Treatment of depression secondary to pain (dsp)

Country Status (6)

Country Link
EP (1) EP1545489A4 (fr)
CN (1) CN1671368A (fr)
AU (1) AU2003268020A1 (fr)
CA (1) CA2493490A1 (fr)
MX (1) MXPA05000566A (fr)
WO (1) WO2004009069A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200639162A (en) 2005-03-14 2006-11-16 Teva Pharma Pure duloxetine hydrochloride
FR2978350B1 (fr) 2011-07-28 2013-11-08 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
CN112500361B (zh) * 2020-12-27 2023-05-12 甘肃瀚聚药业有限公司 一种(s)-4-苯基-2-恶唑烷酮的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0647134A4 (fr) * 1992-06-23 1997-07-30 Sepracor Inc Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure.
CA2134038C (fr) * 1994-06-16 1997-06-03 David Taiwai Wong Potentialisation des effets de medicaments
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome

Also Published As

Publication number Publication date
CN1671368A (zh) 2005-09-21
WO2004009069A1 (fr) 2004-01-29
EP1545489A1 (fr) 2005-06-29
MXPA05000566A (es) 2005-08-29
EP1545489A4 (fr) 2006-08-23
CA2493490A1 (fr) 2004-01-29

Similar Documents

Publication Publication Date Title
US20040034101A1 (en) Treatment and prevention of depression secondary to pain (DSP)
US7888342B2 (en) Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
AU2003284005B2 (en) Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
EP2322225B1 (fr) Inhibiteurs sélectifs de récaptage de la norépinéphrine et de la sérotonine utilisés dans le traitement du syndrome de la fibromyosite, de l'encéphalo-myélite myalgique et de la douleur
US20080096872A1 (en) Composition for Treatment of Pain Specification
US20130236573A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
CN102573823B (zh) 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途
AU2016203771A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
Lew Selegiline orally disintegrating tablets for the treatment of Parkinson’s disease
ES2390225T3 (es) Combinación del analéptico modafinilo y de un antidepresivo para el tratamiento de la depresión
AU2003268020A1 (en) Treatment of depression secondary to pain (dsp)
CA2973540A1 (fr) Traitement de maladie auto-immune chez un patient recevant en outre un betabloquant
Korn et al. Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline
EP1261324B1 (fr) Utilisation du tramadol pour la preparation d'un medicament pour le traitement de troubles gastro-intestinaux fonctionnels
AU2013203567A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
AU2012307535A1 (en) Combinations comprising a S1P receptor modulator
AU2013201492A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application